PEXEVA Drug Patent Profile
✉ Email this page to a colleague
When do Pexeva patents expire, and what generic alternatives are available?
Pexeva is a drug marketed by Sebela Ireland Ltd and is included in one NDA. There is one patent protecting this drug.
This drug has forty patent family members in twenty-five countries.
The generic ingredient in PEXEVA is paroxetine mesylate. There are thirty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pexeva
A generic version of PEXEVA was approved as paroxetine mesylate by ACTAVIS LABS FL INC on June 20th, 2017.
Summary for PEXEVA
| International Patents: | 40 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 19 |
| Clinical Trials: | 1 |
| Patent Applications: | 195 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for PEXEVA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PEXEVA |
| What excipients (inactive ingredients) are in PEXEVA? | PEXEVA excipients list |
| DailyMed Link: | PEXEVA at DailyMed |
Recent Clinical Trials for PEXEVA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sheppard Pratt Health System | N/A |
| Central Michigan University | N/A |
Pharmacology for PEXEVA
| Drug Class | Serotonin Reuptake Inhibitor |
| Mechanism of Action | Serotonin Uptake Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for PEXEVA
US Patents and Regulatory Information for PEXEVA
PEXEVA is protected by one US patents.
Patents protecting PEXEVA
Crystalline paroxetine methane sulfonate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-001 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-004 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-002 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-003 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PEXEVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-002 | Jul 3, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-002 | Jul 3, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-003 | Jul 3, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-001 | Jul 3, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-003 | Jul 3, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-004 | Jul 3, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-004 | Jul 3, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PEXEVA
See the table below for patents covering PEXEVA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2230516 | ⤷ Try a Trial | |
| Norway | 20042101 | ⤷ Try a Trial | |
| Slovakia | 161999 | 4-PHENYLPIPERIDINE COMPOUNDS | ⤷ Try a Trial |
| Denmark | 0994872 | ⤷ Try a Trial | |
| Israel | 133366 | 4-Phenylpiperidine compounds, process for their preparation and uses thereof | ⤷ Try a Trial |
| Germany | 20220955 | ⤷ Try a Trial | |
| South Korea | 20010013615 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
